Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.

Josephine M N Lopes Cardozo Caroline A DrukkerEmiel J T RutgersMarjanka K Schmidt Annuska M GlasAnke WitteveenFatima Cardoso Martine J Piccart Laura J EssermanCoralie PoncetLaura van 't Veer

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Patients with an ultralow-risk 70-gene signature have the best prognosis, distinctive from low risk, with 8-year BCSS above 99%, and very few patients developed distant metastases with an 8-year DMFI rate of 97%. These patients could be candidates for further de-escalation of treatment, to avoid overtreatment and the risk of side effects.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
gene expression
copy number
dna methylation
patient reported
genome wide identification
free survival